Skip to content
Resources > Reports

Opportunities for Private Equity: Finding Growth in a Downturn

Private equity has performed well even in the most volatile times. However, we now enter a period where the outlook is uncertain. Mounting concerns over a downturn continue to be driven by geopolitical instability, changing societal expectations, pockets of market excess and sector disruption, and the overall length of the current economic expansion.

As economic uncertainty persists, growth slows down, and capital becomes more scarce, it is imperative for firms to streamline operations and mitigate risk in order to win big. For PE firms who are upping their game operationally, there’s still plenty of opportunity in a downturn.

In this whitepaper, you’ll learn:

  • What PE leaders can expect from the forthcoming economic downturn
  • How ESG investing is evolving—among investors and corporate narratives
  • The power AI plays in sourcing lucrative deals and bringing them over the finish line

Explore more

APAC Macro Briefing 2026: Risk Meets Opportunity

In this report, we show how resources and workflows available in the AlphaSense platform can help contextualize the APAC macro environment, exploring the key implications for corporate leaders and investors across sectors.
Title slide for "APAC Macro Briefing 2026: Risk Meets Opportunity" with a map of the Asia-Pacific region.

Top AI Use Cases for Private Equity

In this report, discover how private equity teams are leveraging AI to accelerate conviction with speed. With purpose built, AI-driven solutions like AlphaSense, teams are gaining a competitive advantage with custom workflows and unmatched content sets for the most differentiated deal intelligence.
Top AI Use Cases For Private Equity by Barb Tague, Financial Research Leader. Illustration featuring isometric buildings and currency symbols.

AI in Drug Development 2026: From Experimentation to Execution

Learn how AI is reshaping drug development in real time, turning AI execution into a key competitive differentiator.
Presentation slide titled "AI in Drug Development 2026: From Experimentation to Execution" by Sara Mallatt and Sean Carmichael, with line art of laboratory equipment.

Transform intelligence
into advantage

Develop bold strategies, seize opportunities,
and lead with clarity and confidence.